Ipilimumab Filing For Metastatic Melanoma Planned Despite Phase III Failure

Despite failing to meet the primary endpoint of a key study, Medarex/Bristol-Myers Squibb's investigational CTLA-4 inhibitor ipilimumab should be approved by regulators based on the totality of the data from the registration program and the limited treatment options for metastatic melanoma patients, the companies maintained